The Biological Safety Testing Products and Services Market was valued at USD 5.84 billion in 2025 and is projected to reach USD 14.66 billion by 2033, growing at a CAGR of 12.20% from 2026 to 2033. The market is witnessing steady expansion driven by increasing biopharmaceutical production, stringent regulatory requirements for product safety, and growing investments in vaccine, cell therapy, and biologics development.
The rising prevalence of chronic and infectious diseases worldwide, coupled with the growing demand for biologics, biosimilars, vaccines, and advanced therapy medicinal products, is encouraging pharmaceutical and biotechnology companies to adopt comprehensive biological safety testing solutions. Sterility testing, endotoxin testing, mycoplasma detection, adventitious agent testing, and viral safety assessments have become critical components of product development and quality assurance processes, ensuring regulatory compliance and patient safety while supporting the commercialization of innovative therapeutics.